Prediction: Oracle Stock Could Hit This Price by 2027

Oracle shares are down 33% in 2026, but the article argues the selloff is overstated versus a large backlog: RPO was $638B vs $67.4B fiscal-2026 revenue. Management expects revenue to rise ~33% to $90B in fiscal 2027 as 12% of RPO converts to revenue over the next year, with revenue conversion potentially reaching 34% over 13–36 months. Offsetting this, debt rose to $167.4B (+$43B YoY) with plans to raise another ~$40B in fiscal 2027, implying dilution from a $20B equity raise; nonetheless, analysts project EPS growth from +5.4% (FY27) to +36% (FY28) and an ~85% upside to a $328 price scenario under a 30x earnings valuation.

Analysis

The market is likely pricing the wrong variable: not whether Oracle can grow, but how much of that growth survives dilution and rising interest burden. Backlog is useful only if it converts at acceptable margin and without repeated external funding; until then, the stock deserves a discount to faster-growing AI beneficiaries with cleaner balance sheets. In the next 2-6 weeks, the shares can still bounce on any reaffirmation of financing or demand, but the multiple expansion case is capped by per-share economics.

The better second-order winner is NVDA, plus the broader AI infrastructure supply chain, because Oracle’s build-out effectively forwards demand into GPUs, networking, power gear, and colocation inputs. If Oracle has to keep issuing equity or debt to fund data centers, that is a margin transfer away from ORCL shareholders and toward suppliers that monetize capex immediately. Credit investors should also watch ORCL paper supply; repeated issuance can pressure tech IG spreads at the margin, even if absolute default risk stays low.

The key catalyst window is 1-3 months around the next earnings/financing update, when investors can test whether RPO conversion and FCF are tracking the promised step-up. The contrarian risk is that consensus is treating backlog as earnings already earned; if capacity constraints, customer concentration, or power availability slow deployment, the stock can de-rate again despite headline growth. Falsifiers: revenue growth coming in below the implied 30%+ run-rate, another large equity raise, or leverage continuing to rise without a visible free-cash-flow inflection. Over 6-18 months, the thesis works only if Oracle proves it can self-fund expansion; otherwise, the equity remains a levered AI claim with execution risk.

Key Decisions for Investors

• Prefer a 3-6 month pair trade: long NVDA / short ORCL. Oracle’s capex cycle should support NVDA demand, while ORCL carries the dilution and leverage overhang; this is the cleaner way to express bullish AI infrastructure.
• Do not chase ORCL outright after a relief rally; wait for confirmation that financing is smaller than feared and that operating cash flow is inflecting. If the next update shows continued debt/equity reliance, use strength to fade.
• Set an alert on Oracle’s next earnings and financing disclosures: if RPO conversion misses the implied run-rate or net debt keeps climbing faster than revenue, the rerating thesis is broken.
• Watch for relative strength in AI suppliers versus ORCL over the next 1-3 months; if the spread widens further, it supports staying long the picks-and-shovels names and underweighting the levered platform owner.